The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab in MSI/dMMR mCRC
Romain Cohen, MD, PhD, Saint-Antoine Hospital, AP-HP, Paris, France, discusses the results of the GERCOR NIPICOL Phase II study (NCT03350126) evaluating the RECIST and iRECIST criteria for the management of microsatellite instability or mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) patients treated with nivolumab and ipilimumab. The results of the study suggest pseudoprogression is rare in these patients, and that the combined immune checkpoint blockade therapy results in impressive disease control rates and survival outcomes. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
